DrugPatentWatch Database Preview
ATROVENT HFA Drug Profile
» See Plans and Pricing
When do Atrovent Hfa patents expire, and what generic alternatives are available?
Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this drug.
This drug has sixty patent family members in thirty-eight countries.
The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
US ANDA Litigation and Generic Entry Outlook for Atrovent Hfa
A generic version of ATROVENT HFA was approved as ipratropium bromide by RITEDOSE CORP on January 26th, 2001.
Summary for ATROVENT HFA
| International Patents: | 60 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 12 |
| Clinical Trials: | 42 |
| Patent Applications: | 4,184 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ATROVENT HFA |
| Drug Sales Revenues: | Drug sales revenues for ATROVENT HFA |
| DailyMed Link: | ATROVENT HFA at DailyMed |
See drug prices for ATROVENT HFA
Recent Clinical Trials for ATROVENT HFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Simbec Research | Phase 1 |
| AstraZeneca | Phase 1 |
| London Health Sciences Centre | Phase 2 |
Pharmacology for ATROVENT HFA
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
US Patents and Regulatory Information for ATROVENT HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATROVENT HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | Start Trial | Start Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | Start Trial | Start Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | Start Trial | Start Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATROVENT HFA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1011620 | Start Trial |
| Japan | H08509459 | Start Trial |
| Estonia | 04394 | Start Trial |
| Romania | 117414 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
